The US Food and Drug Administration (FDA) has approved injectable drugs and infusion technologies Hospira's Symbiq 3.13 infusion device, the improved version of the company's infusion system platform.
The Symbiq infusion system allows clinicians to help improve workflow and decrease medication errors.
Symbiq platform enhancements include improved connectivity and wireless communication to enhance intravenous (I.V.) clinical integration, improved software reliability, enabling consistent performance across a range of clinical applications, and updated software design that supports optimal performance.
Symbiq infusion pump uses Hospira MedNet safety software to provide additional medication-error protection by requiring users to select a drug library entry from the safety software for all drug delivery programmes.
Hospira chief scientific officer Sumant Ramachandra said with the new Symbiq system, the company will provide clinicians and patients with technologically advanced and quality infusion pump.
"We took a device that was designed to transform how hospitals deliver medications safely and reflect real-world clinician feedback, and then put the system through a rigorous development and regulatory process to increase its reliability," Ramachandra added.
Hospira plans to upgrade to the Symbiq device in the first quarter and expects to begin shipments in the second quarter of this year.